Literature DB >> 12909720

Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity.

Michael A Resnick1, Alberto Inga.   

Abstract

There are many sources of genetic diversity, ranging from programmed mutagenesis in antibody genes to random mutagenesis during species evolution or development of cancer. We propose that mutations in DNA sequence-specific transcription factors that target response elements (REs) in many genes can also provide for rapid and broad phenotypic diversity, if the mutations lead to altered binding affinities at individual REs. To test this concept, we examined the in vivo transactivation capacity of wild-type human and murine p53 and 25 partial function mutants. The p53s were expressed in yeast from a rheostatable promoter, and the transactivation capacities toward >15 promoter REs upstream of a reporter gene were measured. Surprisingly, there was wide variation in transactivation by the mutant p53s toward the various REs. This is the first study to address directly the impact of mutations in a sequence-specific transcription factor on transactivation from a wide array of REs. We propose a master gene hypothesis for phenotypic diversity where the master gene is a single transcriptional activator (or repressor) that regulates many genes through different REs. Mutations of the master gene can lead to a variety of simultaneous changes in both the selection of targets and the extent of transcriptional modulation at the individual targets, resulting in a vast number of potential phenotypes that can be created with minimal mutational changes without altering existing protein-protein interactions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12909720      PMCID: PMC187891          DOI: 10.1073/pnas.1633803100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  54 in total

1.  Rapid evolution of cis-regulatory sequences via local point mutations.

Authors:  J R Stone; G A Wray
Journal:  Mol Biol Evol       Date:  2001-09       Impact factor: 16.240

2.  Accelerated regulatory gene evolution in an adaptive radiation.

Authors:  M Barrier; R H Robichaux; M D Purugganan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

Review 3.  The rise and fall of mutator bacteria.

Authors:  A Giraud; M Radman; I Matic; F Taddei
Journal:  Curr Opin Microbiol       Date:  2001-10       Impact factor: 7.934

Review 4.  Transcription factors as targets for cancer therapy.

Authors:  James E Darnell
Journal:  Nat Rev Cancer       Date:  2002-10       Impact factor: 60.716

5.  In vivo site-directed mutagenesis using oligonucleotides.

Authors:  F Storici; L K Lewis; M A Resnick
Journal:  Nat Biotechnol       Date:  2001-08       Impact factor: 54.908

6.  p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay.

Authors:  A Inga; P Monti; G Fronza; T Darden; M A Resnick
Journal:  Oncogene       Date:  2001-01-25       Impact factor: 9.867

7.  Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein.

Authors:  Andrew C R Martin; Angelo M Facchiano; Alison L Cuff; Tina Hernandez-Boussard; Magali Olivier; Pierre Hainaut; Janet M Thornton
Journal:  Hum Mutat       Date:  2002-02       Impact factor: 4.878

8.  An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma.

Authors:  R C Ribeiro; F Sandrini; B Figueiredo; G P Zambetti; E Michalkiewicz; A R Lafferty; L DeLacerda; M Rabin; C Cadwell; G Sampaio; I Cat; C A Stratakis; R Sandrini
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

9.  Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.

Authors:  A Inga; M A Resnick
Journal:  Oncogene       Date:  2001-06-07       Impact factor: 9.867

10.  p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.

Authors:  P Campomenosi; P Monti; A Aprile; A Abbondandolo; T Frebourg; B Gold; T Crook; A Inga; M A Resnick; R Iggo; G Fronza
Journal:  Oncogene       Date:  2001-06-14       Impact factor: 9.867

View more
  57 in total

1.  A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network.

Authors:  Daniel Menendez; Oliver Krysiak; Alberto Inga; Bianca Krysiak; Michael A Resnick; Gilbert Schönfelder
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

2.  Low-level p53 expression changes transactivation rules and reveals superactivating sequences.

Authors:  Jennifer J Jordan; Daniel Menendez; Jenia Sharav; Itai Beno; Karin Rosenthal; Michael A Resnick; Tali E Haran
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-20       Impact factor: 11.205

3.  Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors.

Authors:  Karolina Edlund; Ola Larsson; Adam Ameur; Ignas Bunikis; Ulf Gyllensten; Bernard Leroy; Magnus Sundström; Patrick Micke; Johan Botling; Thierry Soussi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-24       Impact factor: 11.205

4.  Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes.

Authors:  Paola Monti; Chiara Perfumo; Alessandra Bisio; Yari Ciribilli; Paola Menichini; Debora Russo; David M Umbach; Michael A Resnick; Alberto Inga; Gilberto Fronza
Journal:  Mol Cancer Res       Date:  2011-02-22       Impact factor: 5.852

5.  A single-nucleotide polymorphism in a half-binding site creates p53 and estrogen receptor control of vascular endothelial growth factor receptor 1.

Authors:  Daniel Menendez; Alberto Inga; Joyce Snipe; Oliver Krysiak; Gilbert Schönfelder; Michael A Resnick
Journal:  Mol Cell Biol       Date:  2007-01-22       Impact factor: 4.272

Review 6.  The expanding universe of p53 targets.

Authors:  Daniel Menendez; Alberto Inga; Michael A Resnick
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

7.  Estrogen receptor acting in cis enhances WT and mutant p53 transactivation at canonical and noncanonical p53 target sequences.

Authors:  Daniel Menendez; Alberto Inga; Michael A Resnick
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

8.  Codon 104 variation of p53 gene provides adaptive apoptotic responses to extreme environments in mammals of the Tibet plateau.

Authors:  Yang Zhao; Ji-Long Ren; Ming-Yang Wang; Sheng-Ting Zhang; Yu Liu; Min Li; Yi-Bin Cao; Hu-Yue Zu; Xiao-Cheng Chen; Chung-I Wu; Eviatar Nevo; Xue-Qun Chen; Ji-Zeng Du
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

9.  Parallel analysis of tetramerization domain mutants of the human p53 protein using PCR colonies.

Authors:  Joshua Merritt; Kim G Roberts; James A Butz; Jeremy S Edwards
Journal:  Genomic Med       Date:  2007-09-05

10.  The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30.

Authors:  Ophira M Ginsburg; Mohammad R Akbari; Zeba Aziz; Robert Young; Henry Lynch; Parviz Ghadirian; Andre Robidoux; Julian Londono; Gonzalo Vasquez; Magda Gomes; Mauricio Magalhaes Costa; Constantine Dimitrakakis; Gustavo Gutierrez; Robert Pilarski; Robert Royer; Steven A Narod
Journal:  Fam Cancer       Date:  2009       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.